ADHERENCE TO NEBULISED THERAPIES IN PEOPLE WITH CYSTIC FIBROSIS STARTING ELEXACAFTOR/TEZACAFTOR/IVACAFTOR (KAFTRIO)

被引：1
|
作者：
Howell, I. B. [1 ]
Tugwell, A. [1 ]
Bhaskaran, D. [1 ]
Bell, N. J. [1 ]
机构：
[1] Bristol Adult Cyst Fibrosis Ctr, Bristol, Avon, England
来源：
THORAX | 2021年 / 76卷
关键词：
D O I：
10.1136/thorax-2021-BTSabstracts.65
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
S59
引用
收藏
页码：A40 / A40
页数：1
相关论文
共 50 条
  • [21] Cardiopulmonary exercise test (CPET) in people with Cystic Fibrosis on elexacaftor/tezacaftor/ivacaftor therapy
    Retucci, Mariangela
    Gramegna, Andrea
    Colombo, Crizia
    Gambazza, Simone
    Mariani, Alessandra
    Tammaro, Serena
    Vicenzi, Marco
    Russo, Maria
    Tomarelli, Irene
    Dacco, Valeria
    Blasi, Francesco
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64
  • [22] Papilledema and hypervitaminosis A after elexacaftor/tezacaftor/ivacaftor for cystic fibrosis
    Miller, Matthew J.
    Foroozan, Rod
    CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE, 2022, 57 (01): : E6 - E10
  • [23] Early insurance coverage of elexacaftor/tezacaftor/ivacaftor for cystic fibrosis
    Anderson, Ashlee
    McCoy, Lindsey
    Pettit, Rebecca S.
    Wright, Brittany A.
    Lubsch, Lisa
    PEDIATRIC PULMONOLOGY, 2021, 56 (12) : 4053 - 4054
  • [24] A systematic review of the impact of Elexacaftor/Tezacaftor/Ivacaftor on body composition in people with cystic fibrosis
    Kinsey, Laura
    Winterbottom, Hannah
    Hudson, Lydia
    Lal, Simon
    Jones, Andrew M.
    Burden, Sorrel
    EUROPEAN JOURNAL OF CLINICAL NUTRITION, 2025,
  • [25] Elexacaftor tezacaftor ivacaftor therapy alters plasma sphingolipid profiles in people with cystic fibrosis
    Westhoelter, D.
    Schumacher, F.
    Wuelfinghoff, N.
    Sutharsan, S.
    Strassburg, S.
    Kleuser, B.
    Horn, P. A.
    Reuter, S.
    Gulbins, E.
    Taube, C.
    Welsner, M.
    EUROPEAN RESPIRATORY JOURNAL, 2022, 60
  • [26] MEDICATION ACCESS BARRIERS FOR ELEXACAFTOR/TEZACAFTOR/IVACAFTOR-ELIGIBLE PEOPLE WITH CYSTIC FIBROSIS
    Dieni, O.
    Ryan, L.
    Stocks, A.
    Erdo, J.
    PEDIATRIC PULMONOLOGY, 2020, 55 : S359 - S359
  • [27] Impact of elexacaftor/tezacaftor/ivacaftor on depression and anxiety in cystic fibrosis
    Zhang, Lijia
    Albon, Dana
    Jones, Marieke
    Bruschwein, Heather
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2022, 16
  • [28] HOW ELEXACAFTOR/TEZACAFTOR/IVACAFTOR IS CHANGING SPUTUM CULTURE COLLECTION FOR PEOPLE WITH CYSTIC FIBROSIS
    Pai, S.
    Villagomez, K.
    Dorsett, S.
    Guthrie, C. P.
    PEDIATRIC PULMONOLOGY, 2020, 55 : S260 - S260
  • [29] Response to elexacaftor/tezacaftor/ivacaftor in intestinal organoids derived from people with cystic fibrosis
    Furstova, Eva
    Dousova, Tereza
    Beranek, Jakub
    Libik, Malgorzata
    Fila, Libor
    Modrak, Martin
    Cinek, Ondrej
    Macek, Milan, Jr.
    Drevinek, Pavel
    JOURNAL OF CYSTIC FIBROSIS, 2022, 21 (02) : 243 - 245
  • [30] Use of Chronic Maintenance Therapies for Cystic Fibrosis in Patients on Elexacaftor, Tezacaftor, and Ivacaftor at a Single Center
    Toporek, A.
    Merlo, C. A.
    West, N. E.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
12345